Report Top Line Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Report top line data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Report Top Line Data Today - Breaking & Trending Today

Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United States , San Diego , Linda Marb , Los Angeles , Exchange Commission , Ns Pharma Inc , Capricor Therapeutics Inc , World Muscle Society , Division Of Microbiology , Human Services , International Annual Congress , Exosome Program , Globenewswire Inc , Capricor Company Contact , Us Department Of Health , National Institutes Of Health , Duchenne Muscular Dystrophy Program , Drug Administration , National Institute Of Allergy , Nippon Shinyaku Co Ltd , Enrollment Complete , Duchenne Muscular Dystrophy , Announced Successful Interim Futility Analysis , Report Top Line Data , Upcoming Typeb Meeting , Discuss Commercial Manufacturing Planning ,

Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress

Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
Total Revenues of $23.3 Million for the First Quarter of 2021; XPOVIO® (selinexor) Net Product Sales of $21.7 Million
Conditional Marketing Authorization Granted by the European Commission for NEXPOVIO® (selinexor) in Penta-Refractory Multiple Myeloma; European Decision for Expanded Multiple Myeloma Indication Expected in the Fourth Quarter of 2021
Richard Paulson Appointed Next President and Chief Executive Officer of Karyopharm
Conference Call Scheduled for Today at 8:30 a.m. ET
News provided by
Share this article
Share this article
NEWTON, Mass., May 3, 2021 /PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended March 31, 2021. In addition, Karyopharm highlighted select corporate milestones, including ....

United States , Michaelg Kauffman , Richard Paulson , Sharon Shacham , Selective Inhibitor Of Nuclear Export , American Society Of Clinical Oncology , Takeda Pharmaceutical Company , Karyopharm Selective Inhibitor Of Nuclear Export , European Union , Committee For Medicinal Products Human Use , Information Department , Karyopharm Therapeutics Inc , Drug Administration , European Commission , Progress Towards The International Expansion , Exchange Commission , Ipsen Pharmaceuticals Inc , Development For Solid Tumors , European Medicines Agency , European Commission Ec Grants Conditional Marketing Authorization , Israeli Ministry Of Health , Karyopharm Therapeutics , Chief Executive Officer , Paulson Named Next President , Executive Vice President , Ipsen Pharmaceuticals ,